Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|July 8, 2011
How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence?Philippe Colucci, Jacques Turgeon, Murray P Ducharme
European Endocrinology|October 24, 2018
A Review of the Pharmacokinetics of Levothyroxine for the Treatment of HypothyroidismPhilippe Colucci, Corinne Seng Yue, Murray Ducharme, et al.
Therapeutic Drug Monitoring|April 26, 2011
Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditionsPhilippe Colucci, Pina D'Angelo, Giuseppe Mautone, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2008
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteersPhilippe Colucci, John C Pottage, Heather Robison, et al.
Therapeutic Drug Monitoring|September 14, 2011
Performance of different population pharmacokinetic algorithmsPhilippe Colucci, Julie Grenier, Corinne Seng Yue, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|November 9, 2018
Revisiting FDA's 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based RecommendationsDeniz Ozdin, Naveen Sharma, Jorge Lujan-Zilbermann, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2008
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjectsPhilippe Colucci, John C Pottage, Heather Robison, et al.
Cancer|August 28, 2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinomaFrancisco J Esteva, Edgardo Rivera, Massimo Cristofanilli, et al.
Clinical Drug Investigation|September 27, 2017
Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy SubjectsMary Bond, Laura Rabinovich-Guilatt, Sally Selim, et al.
Pageof 1